ストックスクリーナーアプリを入手
23.57
1.29%
0.30
プレマーケット:
23.32
-0.25
-1.06%
Xoma Royalty Corp (XOMA) 最新ニュース
Xoma stock rating reinstated as Hold by TD Cowen after Generation Bio acquisition - Investing.com South Africa
Buyback Watch: What drives XOMA Royalty Corporations stock priceJuly 2025 Market Mood & Risk Controlled Stock Alerts - baoquankhu1.vn
XOMA Royalty (NASDAQ:XOMA) Upgraded at Zacks Research - Defense World
XOMA Royalty (NASDAQ:XOMA) Upgraded by Zacks Research to "Hold" Rating - MarketBeat
XOMA Royalty’s Preferreds Still Offer Compelling Income Despite Call Risk (NASDAQ:XOMA) - Seeking Alpha
Generation Bio pays landlord $21.5M to escape lease early after Xoma buyout - The Business Journals
XOMA Royalty (XOMA) Stock Price, News & Analysis - MarketBeat
XOMA Royalty completes acquisition of Generation Bio for $4.29 per share By Investing.com - Investing.com South Africa
XOMA Royalty completes acquisition of Generation Bio for $4.29 per share - Investing.com Nigeria
XOMA Royalty completes acquisition of Generation Bio; GBIO delisted from Nasdaq - Investing.com
XOMA Completes Acquisition and Delisting of Generation Bio - TipRanks
XOMA Royalty Completes Generation Bio Acquisition and Merger - TipRanks
XOMA Royalty Corporation Completes Acquisition of Generation Bio Co. Through Tender Offer - Quiver Quantitative
Generation Bio investors cashed out at $4.2913 a share in XOMA takeover - Stock Titan
Published on: 2026-02-09 02:34:15 - baoquankhu1.vn
Gainers Report: What is the next catalyst for XOMA Royalty CorporationShare Buyback & Accurate Intraday Trading Signals - baoquankhu1.vn
Analysts Set XOMA Royalty Corporation (NASDAQ:XOMA) Target Price at $60.60 - Defense World
Short Interest in XOMA Royalty Corporation (NASDAQ:XOMA) Grows By 56.7% - MarketBeat
XOMA Royalty Corporation (NASDAQ:XOMA) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Analyzing XOMA Royalty (NASDAQ:XOMA) and Ascendis Pharma A/S (NASDAQ:ASND) - Defense World
Risk Off: What is the next catalyst for XOMA Royalty Corporation2025 Volume Leaders & Short-Term High Return Strategies - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - GlobeNewswire Inc.
Institutional owners may take dramatic actions as XOMA Royalty Corporation's (NASDAQ:XOMA) recent 12% drop adds to one-year losses - Yahoo Finance
Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty CorporationXOMA - marketscreener.com
XOMA Royalty Corp (NASDAQ: XOMA) appoints new CFO, sets pay terms - stocktitan.net
XOMA Royalty CFO Thomas Burns steps down, Jeffrey Trigilio appointed - Investing.com
XOMA royalty announces CFO transition - MSN
XOMA Royalty Corporation Announces CFO Transition as Thomas Burns Steps Down and Jeffrey Trigilio Takes Over - Quiver Quantitative
Biotech royalty firm XOMA shifts finance leadership after nearly 20 years - Stock Titan
Is XOMA Royalty Corporation stock a defensive play in 20252025 Investor Takeaways & Reliable Price Breakout Signals - Улправда
Will XOMA Royalty Corporation (X0M1) stock profit from fiscal stimulus2026 world cup usa national team quarterfinals top scorers counter attacking tactical prediction breakdown - ulpravda.ru
Implied Volatility Surging for XOMA Royalty Stock Options - Yahoo Finance
XOMA Royalty Corporation (NASDAQ:XOMA) Given Average Rating of “Hold” by Analysts - Defense World
Takeda, XOMA ink new royalty agreement; amend existing deal - MSN
Xoma royalty corp sees sale of $16.98 million in stock by investors - MSN
Antibody Development Company Cleared to Pursue Royalties for Tremfya, Judge Rules - Law.com
Can XOMA Royalty Corporation stock double in next 5 yearsTechnical Analysis Insights & Free Trend Following Techniques - bollywoodhelpline.com
Leerink Partners reiterates Outperform rating on XOMA stock at $45 target - Investing.com India
XOMA and Takeda execute royalty sharing transaction - The Pharma Letter
Takeda regains majority of mezagitamab royalty interest from XOMA - Investing.com
XOMA Royalty: Entitled to Payments Associated - 富途牛牛
Drug royalties reshuffled as XOMA trades part of one for nine experimental drugs - Stock Titan
XOMA Royalty Corporation (NASDAQ:XOMA) Short Interest Up 31.7% in December - MarketBeat
XOMA Royalty (XOMAO) Stock Analysis Report | Financials & Insights - Benzinga
XOMA Royalty Declares Quarterly Preferred Stock Dividends - Sahm
XOMA Royalty Corporation Announces Cash Dividends for Preferred Stockholders - Quiver Quantitative
Two XOMA preferred share classes pay cash to holders in January - Stock Titan
Institutional Owners May Consider Drastic Measures as XOMA Royalty Corporation's (NASDAQ:XOMA) Recent US$57m Drop Adds to Long-term Losses - 富途牛牛
XOMA Royalty (NASDAQ:XOMA) shareholders have earned a 13% CAGR over the last three years - Yahoo Finance
Turnstone Biologics To Merge With Biotech Royalty Aggregator XOMA, But Retail Sentiment Slumps - MSN
Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO - RTTNews
Can XOMA Royalty Corporation stock deliver strong Q4 earningsRate Hike & Smart Investment Allocation Insights - Улправда
Generation Bio is latest Mass. biotech to be acquired by Xoma - The Business Journals
Jefferies downgrades Generation Bio stock to Hold as XOMA acquisition announced - Investing.com
‘Zombie’ biotech buyer Xoma to acquire Generation Bio - Yahoo Finance
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):